Redemplo Injection, Solution
NDC Package 84141-025-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Redemplo (plozasiran) injection is rEDEMPLO is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). This formulation utilizes a injection, solution delivery system. Marketed by Arrowhead Pharmaceuticals, Inc., this product is identified by NDC 84141-025 and is authorized under FDA application NDA219947.

Identification & Billing

NDC Package Code
84141-025-01
Package Description
1 SYRINGE, GLASS in 1 CARTON / 1 mL in 1 SYRINGE, GLASS
Product Code
84141-025
11-Digit Billing Format
84141002501
Billing Unit
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Redemplo
Non-Proprietary Name
Plozasiran
Substance Name
Plozasiran
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
PLOZASIRAN 25 mg/.5mL
Usage Information
REDEMPLO is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).

Regulatory & Marketing

Labeler Name
Arrowhead Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
NDA219947
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
11-19-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 84141-025-01 identifies a specific commercial package of 1 syringe, glass in 1 carton / 1 ml in 1 syringe, glass of Redemplo, a human prescription drug labeled by Arrowhead Pharmaceuticals, Inc.. This injection, solution is formulated for subcutaneous use and contains plozasiran as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Arrowhead Pharmaceuticals, Inc. on November 19, 2025. The current certification is valid through December 31, 2026.

How is this Arrowhead Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 84141002501. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
84141-025-01
11-Digit CMS (5-4-2)
84141-0025-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.